nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Oxidative Stress—SOD3—chronic obstructive pulmonary disease	0.0129	0.169	CbGpPWpGaD
Deferoxamine—XDH—Effects of Nitric Oxide—NOS2—chronic obstructive pulmonary disease	0.012	0.157	CbGpPWpGaD
Deferoxamine—XDH—Effects of Nitric Oxide—NOS3—chronic obstructive pulmonary disease	0.00964	0.126	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—GCLC—chronic obstructive pulmonary disease	0.00843	0.11	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—HMOX1—chronic obstructive pulmonary disease	0.00583	0.0764	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—SOD3—chronic obstructive pulmonary disease	0.00547	0.0716	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—CYP1A1—chronic obstructive pulmonary disease	0.00515	0.0675	CbGpPWpGaD
Deferoxamine—Arrhythmia—Tiotropium—chronic obstructive pulmonary disease	0.00422	0.00457	CcSEcCtD
Deferoxamine—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.00422	0.00456	CcSEcCtD
Deferoxamine—Dysuria—Salbutamol—chronic obstructive pulmonary disease	0.0042	0.00455	CcSEcCtD
Deferoxamine—Infestation—Montelukast—chronic obstructive pulmonary disease	0.00416	0.0045	CcSEcCtD
Deferoxamine—Infestation NOS—Montelukast—chronic obstructive pulmonary disease	0.00416	0.0045	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Montelukast—chronic obstructive pulmonary disease	0.00407	0.00441	CcSEcCtD
Deferoxamine—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.00393	0.00425	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Salbutamol—chronic obstructive pulmonary disease	0.00393	0.00425	CcSEcCtD
Deferoxamine—Vision blurred—Tiotropium—chronic obstructive pulmonary disease	0.00387	0.00419	CcSEcCtD
Deferoxamine—Neuropathy—Prednisolone—chronic obstructive pulmonary disease	0.00386	0.00418	CcSEcCtD
Deferoxamine—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.00378	0.00409	CcSEcCtD
Deferoxamine—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.00376	0.00407	CcSEcCtD
Deferoxamine—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.00376	0.00407	CcSEcCtD
Deferoxamine—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.00376	0.00407	CcSEcCtD
Deferoxamine—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.00374	0.00405	CcSEcCtD
Deferoxamine—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.00374	0.00405	CcSEcCtD
Deferoxamine—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.00373	0.00404	CcSEcCtD
Deferoxamine—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.00373	0.00404	CcSEcCtD
Deferoxamine—Hallucination—Montelukast—chronic obstructive pulmonary disease	0.00371	0.00402	CcSEcCtD
Deferoxamine—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.00369	0.00399	CcSEcCtD
Deferoxamine—Visual impairment—Arformoterol—chronic obstructive pulmonary disease	0.00367	0.00398	CcSEcCtD
Deferoxamine—Visual impairment—Formoterol—chronic obstructive pulmonary disease	0.00367	0.00398	CcSEcCtD
Deferoxamine—XDH—Selenium Micronutrient Network—MPO—chronic obstructive pulmonary disease	0.00367	0.0481	CbGpPWpGaD
Deferoxamine—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.00367	0.00397	CcSEcCtD
Deferoxamine—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.00366	0.00396	CcSEcCtD
Deferoxamine—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00365	0.00395	CcSEcCtD
Deferoxamine—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.00356	0.00385	CcSEcCtD
Deferoxamine—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.00355	0.00385	CcSEcCtD
Deferoxamine—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.00354	0.00383	CcSEcCtD
Deferoxamine—Infection—Aminophylline—chronic obstructive pulmonary disease	0.00353	0.00383	CcSEcCtD
Deferoxamine—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00353	0.00382	CcSEcCtD
Deferoxamine—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.00353	0.00382	CcSEcCtD
Deferoxamine—Shock—Aminophylline—chronic obstructive pulmonary disease	0.0035	0.00379	CcSEcCtD
Deferoxamine—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.0035	0.00379	CcSEcCtD
Deferoxamine—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.0035	0.00379	CcSEcCtD
Deferoxamine—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.00349	0.00378	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00347	0.00376	CcSEcCtD
Deferoxamine—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.00347	0.00376	CcSEcCtD
Deferoxamine—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.00344	0.00373	CcSEcCtD
Deferoxamine—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00344	0.00373	CcSEcCtD
Deferoxamine—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00343	0.00372	CcSEcCtD
Deferoxamine—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00343	0.00372	CcSEcCtD
Deferoxamine—Arrhythmia—Arformoterol—chronic obstructive pulmonary disease	0.0034	0.00369	CcSEcCtD
Deferoxamine—Arrhythmia—Formoterol—chronic obstructive pulmonary disease	0.0034	0.00369	CcSEcCtD
Deferoxamine—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00339	0.00367	CcSEcCtD
Deferoxamine—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.00337	0.00365	CcSEcCtD
Deferoxamine—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00336	0.00364	CcSEcCtD
Deferoxamine—Tinnitus—Salbutamol—chronic obstructive pulmonary disease	0.00335	0.00363	CcSEcCtD
Deferoxamine—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.00335	0.00363	CcSEcCtD
Deferoxamine—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00334	0.00362	CcSEcCtD
Deferoxamine—Infection—Tiotropium—chronic obstructive pulmonary disease	0.00333	0.00361	CcSEcCtD
Deferoxamine—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.00332	0.0036	CcSEcCtD
Deferoxamine—Shock—Tiotropium—chronic obstructive pulmonary disease	0.0033	0.00357	CcSEcCtD
Deferoxamine—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00329	0.00356	CcSEcCtD
Deferoxamine—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.00327	0.00354	CcSEcCtD
Deferoxamine—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.00326	0.00353	CcSEcCtD
Deferoxamine—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00326	0.00353	CcSEcCtD
Deferoxamine—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00325	0.00352	CcSEcCtD
Deferoxamine—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00324	0.00351	CcSEcCtD
Deferoxamine—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.00321	0.00348	CcSEcCtD
Deferoxamine—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.00319	0.00345	CcSEcCtD
Deferoxamine—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.00319	0.00345	CcSEcCtD
Deferoxamine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00317	0.00343	CcSEcCtD
Deferoxamine—Visual disturbance—Prednisolone—chronic obstructive pulmonary disease	0.00315	0.00341	CcSEcCtD
Deferoxamine—Cataract—Prednisone—chronic obstructive pulmonary disease	0.00314	0.0034	CcSEcCtD
Deferoxamine—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.00312	0.00338	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Prednisolone—chronic obstructive pulmonary disease	0.00308	0.00334	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.00306	0.00331	CcSEcCtD
Deferoxamine—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.00303	0.00328	CcSEcCtD
Deferoxamine—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.00303	0.00328	CcSEcCtD
Deferoxamine—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.00301	0.00326	CcSEcCtD
Deferoxamine—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.00301	0.00326	CcSEcCtD
Deferoxamine—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.00297	0.00321	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00291	0.00315	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.0029	0.00314	CcSEcCtD
Deferoxamine—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.00286	0.0031	CcSEcCtD
Deferoxamine—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.00283	0.00306	CcSEcCtD
Deferoxamine—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.00282	0.00306	CcSEcCtD
Deferoxamine—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.00282	0.00306	CcSEcCtD
Deferoxamine—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.00282	0.00306	CcSEcCtD
Deferoxamine—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.00282	0.00306	CcSEcCtD
Deferoxamine—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.00281	0.00305	CcSEcCtD
Deferoxamine—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.00281	0.00304	CcSEcCtD
Deferoxamine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00281	0.00304	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.0028	0.00304	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.0028	0.00304	CcSEcCtD
Deferoxamine—Neuropathy—Prednisone—chronic obstructive pulmonary disease	0.0028	0.00304	CcSEcCtD
Deferoxamine—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.00277	0.00299	CcSEcCtD
Deferoxamine—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.00277	0.00299	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00275	0.00297	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00274	0.00297	CcSEcCtD
Deferoxamine—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.00271	0.00293	CcSEcCtD
Deferoxamine—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.00271	0.00293	CcSEcCtD
Deferoxamine—Oedema—Formoterol—chronic obstructive pulmonary disease	0.00271	0.00293	CcSEcCtD
Deferoxamine—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.00271	0.00293	CcSEcCtD
Deferoxamine—Infection—Formoterol—chronic obstructive pulmonary disease	0.00269	0.00291	CcSEcCtD
Deferoxamine—Infection—Arformoterol—chronic obstructive pulmonary disease	0.00269	0.00291	CcSEcCtD
Deferoxamine—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.00267	0.00289	CcSEcCtD
Deferoxamine—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.00267	0.00289	CcSEcCtD
Deferoxamine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.00266	0.00288	CcSEcCtD
Deferoxamine—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00265	0.00287	CcSEcCtD
Deferoxamine—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00265	0.00287	CcSEcCtD
Deferoxamine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00265	0.00287	CcSEcCtD
Deferoxamine—Oedema—Montelukast—chronic obstructive pulmonary disease	0.00265	0.00287	CcSEcCtD
Deferoxamine—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.00265	0.00287	CcSEcCtD
Deferoxamine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.00264	0.00286	CcSEcCtD
Deferoxamine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.00264	0.00286	CcSEcCtD
Deferoxamine—Infection—Montelukast—chronic obstructive pulmonary disease	0.00263	0.00285	CcSEcCtD
Deferoxamine—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00263	0.00285	CcSEcCtD
Deferoxamine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00263	0.00285	CcSEcCtD
Deferoxamine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00262	0.00284	CcSEcCtD
Deferoxamine—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.0026	0.00282	CcSEcCtD
Deferoxamine—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.0026	0.00281	CcSEcCtD
Deferoxamine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00258	0.00279	CcSEcCtD
Deferoxamine—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.00256	0.00277	CcSEcCtD
Deferoxamine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.00256	0.00277	CcSEcCtD
Deferoxamine—Infection—Salbutamol—chronic obstructive pulmonary disease	0.00254	0.00275	CcSEcCtD
Deferoxamine—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.00253	0.00274	CcSEcCtD
Deferoxamine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.00253	0.00274	CcSEcCtD
Deferoxamine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00252	0.00272	CcSEcCtD
Deferoxamine—Shock—Salbutamol—chronic obstructive pulmonary disease	0.00251	0.00272	CcSEcCtD
Deferoxamine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00251	0.00271	CcSEcCtD
Deferoxamine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.00249	0.0027	CcSEcCtD
Deferoxamine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00248	0.00269	CcSEcCtD
Deferoxamine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.00247	0.00268	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.00247	0.00267	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00247	0.00267	CcSEcCtD
Deferoxamine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00243	0.00263	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.00242	0.00262	CcSEcCtD
Deferoxamine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.00241	0.00261	CcSEcCtD
Deferoxamine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.00241	0.00261	CcSEcCtD
Deferoxamine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.00239	0.00259	CcSEcCtD
Deferoxamine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.00238	0.00258	CcSEcCtD
Deferoxamine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.00237	0.00257	CcSEcCtD
Deferoxamine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00235	0.00255	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00234	0.00253	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00234	0.00253	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00233	0.00252	CcSEcCtD
Deferoxamine—Pain—Arformoterol—chronic obstructive pulmonary disease	0.00231	0.00251	CcSEcCtD
Deferoxamine—Pain—Formoterol—chronic obstructive pulmonary disease	0.00231	0.00251	CcSEcCtD
Deferoxamine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.0023	0.00248	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00229	0.00248	CcSEcCtD
Deferoxamine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.00228	0.00247	CcSEcCtD
Deferoxamine—Pain—Montelukast—chronic obstructive pulmonary disease	0.00227	0.00245	CcSEcCtD
Deferoxamine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00226	0.00245	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.00225	0.00244	CcSEcCtD
Deferoxamine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00223	0.00241	CcSEcCtD
Deferoxamine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.00222	0.0024	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00221	0.0024	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00221	0.0024	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00221	0.00239	CcSEcCtD
Deferoxamine—Pain—Salbutamol—chronic obstructive pulmonary disease	0.00219	0.00237	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00217	0.00235	CcSEcCtD
Deferoxamine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.00215	0.00233	CcSEcCtD
Deferoxamine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.00215	0.00233	CcSEcCtD
Deferoxamine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.00214	0.00232	CcSEcCtD
Deferoxamine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.00214	0.00232	CcSEcCtD
Deferoxamine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.00214	0.00232	CcSEcCtD
Deferoxamine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.00214	0.00232	CcSEcCtD
Deferoxamine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00213	0.00231	CcSEcCtD
Deferoxamine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00211	0.00229	CcSEcCtD
Deferoxamine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.00211	0.00228	CcSEcCtD
Deferoxamine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.0021	0.00227	CcSEcCtD
Deferoxamine—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.0021	0.00227	CcSEcCtD
Deferoxamine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.0021	0.00227	CcSEcCtD
Deferoxamine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.0021	0.00227	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.00209	0.00226	CcSEcCtD
Deferoxamine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.00203	0.0022	CcSEcCtD
Deferoxamine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00202	0.00219	CcSEcCtD
Deferoxamine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.00202	0.00219	CcSEcCtD
Deferoxamine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00199	0.00216	CcSEcCtD
Deferoxamine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00199	0.00216	CcSEcCtD
Deferoxamine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00199	0.00216	CcSEcCtD
Deferoxamine—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.00199	0.00215	CcSEcCtD
Deferoxamine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.00195	0.00211	CcSEcCtD
Deferoxamine—XDH—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	0.00193	0.0253	CbGpPWpGaD
Deferoxamine—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00192	0.00207	CcSEcCtD
Deferoxamine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00192	0.00207	CcSEcCtD
Deferoxamine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.00188	0.00204	CcSEcCtD
Deferoxamine—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00188	0.00203	CcSEcCtD
Deferoxamine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.00185	0.00201	CcSEcCtD
Deferoxamine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.00185	0.00201	CcSEcCtD
Deferoxamine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.00184	0.002	CcSEcCtD
Deferoxamine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00181	0.00196	CcSEcCtD
Deferoxamine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.00181	0.00196	CcSEcCtD
Deferoxamine—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.0018	0.00194	CcSEcCtD
Deferoxamine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00179	0.00194	CcSEcCtD
Deferoxamine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00179	0.00194	CcSEcCtD
Deferoxamine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00175	0.0019	CcSEcCtD
Deferoxamine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.00175	0.00189	CcSEcCtD
Deferoxamine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.00172	0.00186	CcSEcCtD
Deferoxamine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.00172	0.00186	CcSEcCtD
Deferoxamine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.0017	0.00184	CcSEcCtD
Deferoxamine—Headache—Formoterol—chronic obstructive pulmonary disease	0.0017	0.00184	CcSEcCtD
Deferoxamine—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.00169	0.00183	CcSEcCtD
Deferoxamine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00169	0.00183	CcSEcCtD
Deferoxamine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.00169	0.00183	CcSEcCtD
Deferoxamine—Headache—Montelukast—chronic obstructive pulmonary disease	0.00166	0.0018	CcSEcCtD
Deferoxamine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.00164	0.00178	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.00164	0.00177	CcSEcCtD
Deferoxamine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.00163	0.00176	CcSEcCtD
Deferoxamine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00161	0.00174	CcSEcCtD
Deferoxamine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00161	0.00174	CcSEcCtD
Deferoxamine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.0016	0.00173	CcSEcCtD
Deferoxamine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.00157	0.00171	CcSEcCtD
Deferoxamine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.00156	0.00168	CcSEcCtD
Deferoxamine—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.00153	0.00165	CcSEcCtD
Deferoxamine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.00152	0.00164	CcSEcCtD
Deferoxamine—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.00149	0.00162	CcSEcCtD
Deferoxamine—XDH—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	0.00148	0.0194	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—ALB—chronic obstructive pulmonary disease	0.00148	0.0194	CbGpPWpGaD
Deferoxamine—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.00147	0.0016	CcSEcCtD
Deferoxamine—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.00147	0.00159	CcSEcCtD
Deferoxamine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.00147	0.00159	CcSEcCtD
Deferoxamine—Shock—Prednisolone—chronic obstructive pulmonary disease	0.00144	0.00156	CcSEcCtD
Deferoxamine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.00143	0.00155	CcSEcCtD
Deferoxamine—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.0014	0.00152	CcSEcCtD
Deferoxamine—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.00136	0.00147	CcSEcCtD
Deferoxamine—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.00135	0.00147	CcSEcCtD
Deferoxamine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.00134	0.00145	CcSEcCtD
Deferoxamine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.00132	0.00143	CcSEcCtD
Deferoxamine—Erythema—Prednisone—chronic obstructive pulmonary disease	0.00131	0.00141	CcSEcCtD
Deferoxamine—Pain—Prednisolone—chronic obstructive pulmonary disease	0.00125	0.00136	CcSEcCtD
Deferoxamine—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.00123	0.00133	CcSEcCtD
Deferoxamine—XDH—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	0.0012	0.0158	CbGpPWpGaD
Deferoxamine—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.00119	0.00129	CcSEcCtD
Deferoxamine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.00116	0.00126	CcSEcCtD
Deferoxamine—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.00113	0.00122	CcSEcCtD
Deferoxamine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.00111	0.0012	CcSEcCtD
Deferoxamine—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.00111	0.0012	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.0011	0.00119	CcSEcCtD
Deferoxamine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.00108	0.00117	CcSEcCtD
Deferoxamine—Oedema—Prednisone—chronic obstructive pulmonary disease	0.00107	0.00115	CcSEcCtD
Deferoxamine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.00107	0.00115	CcSEcCtD
Deferoxamine—Infection—Prednisone—chronic obstructive pulmonary disease	0.00106	0.00115	CcSEcCtD
Deferoxamine—Shock—Prednisone—chronic obstructive pulmonary disease	0.00105	0.00113	CcSEcCtD
Deferoxamine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.00104	0.00113	CcSEcCtD
Deferoxamine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.00104	0.00113	CcSEcCtD
Deferoxamine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.00103	0.00112	CcSEcCtD
Deferoxamine—XDH—Metabolism—APIP—chronic obstructive pulmonary disease	0.00102	0.0134	CbGpPWpGaD
Deferoxamine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000971	0.00105	CcSEcCtD
Deferoxamine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000969	0.00105	CcSEcCtD
Deferoxamine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000957	0.00104	CcSEcCtD
Deferoxamine—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000918	0.000994	CcSEcCtD
Deferoxamine—XDH—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	0.000874	0.0114	CbGpPWpGaD
Deferoxamine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000871	0.000943	CcSEcCtD
Deferoxamine—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000871	0.000943	CcSEcCtD
Deferoxamine—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000846	0.000916	CcSEcCtD
Deferoxamine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000842	0.000912	CcSEcCtD
Deferoxamine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000842	0.000912	CcSEcCtD
Deferoxamine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000785	0.00085	CcSEcCtD
Deferoxamine—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000754	0.000816	CcSEcCtD
Deferoxamine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000729	0.000789	CcSEcCtD
Deferoxamine—XDH—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	0.000705	0.00924	CbGpPWpGaD
Deferoxamine—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000704	0.000763	CcSEcCtD
Deferoxamine—XDH—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000679	0.00889	CbGpPWpGaD
Deferoxamine—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000677	0.000733	CcSEcCtD
Deferoxamine—Headache—Prednisone—chronic obstructive pulmonary disease	0.000667	0.000723	CcSEcCtD
Deferoxamine—XDH—Metabolism—GC—chronic obstructive pulmonary disease	0.00066	0.00865	CbGpPWpGaD
Deferoxamine—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000633	0.000685	CcSEcCtD
Deferoxamine—XDH—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000614	0.00804	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.000361	0.00472	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000357	0.00467	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000325	0.00426	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CYP1A2—chronic obstructive pulmonary disease	0.0003	0.00393	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTP1—chronic obstructive pulmonary disease	0.00025	0.00327	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—HMOX1—chronic obstructive pulmonary disease	0.000247	0.00323	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTM1—chronic obstructive pulmonary disease	0.00023	0.00301	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000218	0.00285	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ALB—chronic obstructive pulmonary disease	0.000148	0.00194	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—NOS3—chronic obstructive pulmonary disease	0.000142	0.00186	CbGpPWpGaD
